Elsevier

Respiratory Medicine

Volume 104, Issue 2, February 2010, Pages 296-304
Respiratory Medicine

The SF-36 and SGRQ: Validity and first look at minimum important differences in IPF

https://doi.org/10.1016/j.rmed.2009.09.006Get rights and content
Under an Elsevier user license
open archive

Summary

Rationale

Health-related quality of life (HRQL) is an important outcome in drug trials. Little is known about how the Short Form-36 (SF-36) and Saint George's Respiratory Questionnaire (SGRQ) perform in idiopathic pulmonary fibrosis (IPF).

Objectives

To examine the validity of the SF-36 and SGRQ and to determine scores from each that would constitute a minimum important difference (MID).

Methods

We analyzed data from a recently completed trial that enrolled subjects with well-defined IPF who completed the SF-36, SGRQ, and Baseline/Transition Dyspnea Index at baseline and six months. We compared mean changes in HRQL scores between groups of subjects whose disease severity changed over six months according to clinical anchors (FVC, DLCO, and dyspnea). We estimated the MID for each domain by using both anchor- and distribution-based approaches.

Main results

Results supported the validity of the SF-36 and SGRQ for use in longitudinal studies. Mean changes in domain scores differed significantly between subjects whose clinical status improved and those whose clinical status declined according to the anchors. MID estimates for the SF-36 ranged from 2–4 points and from 5–8 points for the SGRQ.

Conclusion

In IPF, the SF-36 and SGRQ possess reasonable validity for differentiating subjects whose disease severity changes over time. More studies are needed to continue the validation process, to refine estimates of the MIDs for the SF-36 or SGRQ, and to determine if a disease-specific instrument will perform better than either of these.

Keywords

Interstitial lung disease
Pulmonary fibrosis
Quality of life
Validity
Minimum important difference

Cited by (0)